Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.
<h4>Background</h4>Circulating tumor cells (CTCs) are cancer cells that can be isolated via liquid biopsy from blood and can be phenotypically and genetically characterized to provide critical information for guiding cancer treatment. Current analysis of CTCs is hindered by the throughpu...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/03951ce56787415fbd46f96bac1202e5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:03951ce56787415fbd46f96bac1202e5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:03951ce56787415fbd46f96bac1202e52021-11-25T06:09:33ZClinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.1932-620310.1371/journal.pone.0099409https://doaj.org/article/03951ce56787415fbd46f96bac1202e52014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24999991/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Circulating tumor cells (CTCs) are cancer cells that can be isolated via liquid biopsy from blood and can be phenotypically and genetically characterized to provide critical information for guiding cancer treatment. Current analysis of CTCs is hindered by the throughput, selectivity and specificity of devices or assays used in CTC detection and isolation.<h4>Methodology/principal findings</h4>Here, we enriched and characterized putative CTCs from blood samples of patients with both advanced stage metastatic breast and lung cancers using a novel multiplexed spiral microfluidic chip. This system detected putative CTCs under high sensitivity (100%, n = 56) (Breast cancer samples: 12-1275 CTCs/ml; Lung cancer samples: 10-1535 CTCs/ml) rapidly from clinically relevant blood volumes (7.5 ml under 5 min). Blood samples were completely separated into plasma, CTCs and PBMCs components and each fraction were characterized with immunophenotyping (Pan-cytokeratin/CD45, CD44/CD24, EpCAM), fluorescence in-situ hybridization (FISH) (EML4-ALK) or targeted somatic mutation analysis. We used an ultra-sensitive mass spectrometry based system to highlight the presence of an EGFR-activating mutation in both isolated CTCs and plasma cell-free DNA (cf-DNA), and demonstrate concordance with the original tumor-biopsy samples.<h4>Conclusions/significance</h4>We have clinically validated our multiplexed microfluidic chip for the ultra high-throughput, low-cost and label-free enrichment of CTCs. Retrieved cells were unlabeled and viable, enabling potential propagation and real-time downstream analysis using next generation sequencing (NGS) or proteomic analysis.Bee Luan KhooMajid Ebrahimi WarkianiDaniel Shao-Weng TanAli Asgar S BhagatDarryl IrwinDawn Pingxi LauAlvin S T LimKiat Hon LimSai Sakktee KrisnaWan-Teck LimYoon Sim YapSoo Chin LeeRoss A SooJongyoon HanChwee Teck LimPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 7, p e99409 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Bee Luan Khoo Majid Ebrahimi Warkiani Daniel Shao-Weng Tan Ali Asgar S Bhagat Darryl Irwin Dawn Pingxi Lau Alvin S T Lim Kiat Hon Lim Sai Sakktee Krisna Wan-Teck Lim Yoon Sim Yap Soo Chin Lee Ross A Soo Jongyoon Han Chwee Teck Lim Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. |
| description |
<h4>Background</h4>Circulating tumor cells (CTCs) are cancer cells that can be isolated via liquid biopsy from blood and can be phenotypically and genetically characterized to provide critical information for guiding cancer treatment. Current analysis of CTCs is hindered by the throughput, selectivity and specificity of devices or assays used in CTC detection and isolation.<h4>Methodology/principal findings</h4>Here, we enriched and characterized putative CTCs from blood samples of patients with both advanced stage metastatic breast and lung cancers using a novel multiplexed spiral microfluidic chip. This system detected putative CTCs under high sensitivity (100%, n = 56) (Breast cancer samples: 12-1275 CTCs/ml; Lung cancer samples: 10-1535 CTCs/ml) rapidly from clinically relevant blood volumes (7.5 ml under 5 min). Blood samples were completely separated into plasma, CTCs and PBMCs components and each fraction were characterized with immunophenotyping (Pan-cytokeratin/CD45, CD44/CD24, EpCAM), fluorescence in-situ hybridization (FISH) (EML4-ALK) or targeted somatic mutation analysis. We used an ultra-sensitive mass spectrometry based system to highlight the presence of an EGFR-activating mutation in both isolated CTCs and plasma cell-free DNA (cf-DNA), and demonstrate concordance with the original tumor-biopsy samples.<h4>Conclusions/significance</h4>We have clinically validated our multiplexed microfluidic chip for the ultra high-throughput, low-cost and label-free enrichment of CTCs. Retrieved cells were unlabeled and viable, enabling potential propagation and real-time downstream analysis using next generation sequencing (NGS) or proteomic analysis. |
| format |
article |
| author |
Bee Luan Khoo Majid Ebrahimi Warkiani Daniel Shao-Weng Tan Ali Asgar S Bhagat Darryl Irwin Dawn Pingxi Lau Alvin S T Lim Kiat Hon Lim Sai Sakktee Krisna Wan-Teck Lim Yoon Sim Yap Soo Chin Lee Ross A Soo Jongyoon Han Chwee Teck Lim |
| author_facet |
Bee Luan Khoo Majid Ebrahimi Warkiani Daniel Shao-Weng Tan Ali Asgar S Bhagat Darryl Irwin Dawn Pingxi Lau Alvin S T Lim Kiat Hon Lim Sai Sakktee Krisna Wan-Teck Lim Yoon Sim Yap Soo Chin Lee Ross A Soo Jongyoon Han Chwee Teck Lim |
| author_sort |
Bee Luan Khoo |
| title |
Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. |
| title_short |
Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. |
| title_full |
Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. |
| title_fullStr |
Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. |
| title_full_unstemmed |
Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. |
| title_sort |
clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/03951ce56787415fbd46f96bac1202e5 |
| work_keys_str_mv |
AT beeluankhoo clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT majidebrahimiwarkiani clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT danielshaowengtan clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT aliasgarsbhagat clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT darrylirwin clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT dawnpingxilau clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT alvinstlim clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT kiathonlim clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT saisakkteekrisna clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT wantecklim clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT yoonsimyap clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT soochinlee clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT rossasoo clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT jongyoonhan clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells AT chweetecklim clinicalvalidationofanultrahighthroughputspiralmicrofluidicsforthedetectionandenrichmentofviablecirculatingtumorcells |
| _version_ |
1718414083180462080 |